Production and characterization of a murine lymphocyte activating factor by Fox, James Allen
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library School of Medicine
1977




Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation





Permission for photocopying or microfilming of 11 
for the purpose of Individual scholarly consultation or reference Is hereby 
granted by the author. This permission is not to be interpreted as affect¬ 
ing publication of this work or otherwise placing it in the public domain, 
and the author reserves all rights of ownership guaranteed under common 
law protection of unpublished manuscripts. 
Digitized by the Internet Archive 
in 2017 with funding from 
The National Endowment for the Humanities and the Arcadia Fund 
https://archive.org/details/productioncharacOOfoxj 
PRODUCTION AND CHARACTERIZATION OF A 
MURINE LYMPHOCYTE ACTIVATING FACTOR 
James Allen Fox 
B. A., Yale University, 1973 
Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Medicine 
March 1, 1977 

ACKNOWLEDGEMENTS 
I wish to thank my advisor. Dr. R. E. Handschumacher for 
his inspiring guidance of this thesis. He has set high stan¬ 
dards and has been most supportive® I also wish to thank 
Drs. M. S. Mitchell, M. Hacker, G. T. Blyden, and L. B. Lach- 
man for their helpful discussions and insightful advice® 
Ms. A. Clark, Ms. V. Fitzgerald, and Ms. D. Moore have been of 
great assistance with the technical aspects of these studies® 
This work was supported by funds from a grant from the 
American Cancer Society and two summer fellowships from the 





The Role of Macrophages in the Immune Response 
Soluble Leukocyte-Derived Specific Lymphocyte 
Stimulators 
A Non-Specific Lymphocyte Activating Factor (LAF) 
Enhancement of Immune Responsiveness and Its 
Possible Role in Tumor Immunotherapy 
BCG Immunotherapy 
Endotoxin, the Immune Response and Tumor 
Immuno therapy 
METHODS AND MATERIALS 
Animals 
Reagents 
Recovery of -%-LPS from Peritoneal Washings 
Production of Lymphocyte Activating Factor 
The LAF Assay 
Purification and Characterization of LAF 
RESULTS 
Production of LAF in the Peritoneum 
Splenic LAF 




Characterization and Purification of LAF 











































































, • ■< 
DEDICATION 
To my wonderful paxents 

ABSTRACT 
Murine lymphocyte activating factor (LAF), a leukocyte 
product which enhances DNA synthesis in thymocytes, was 
studied. In vivo stimulation with intraperitoneal injections 
of Eh coli lipopolysaccharide (LPS) was employed, and spleen 
and peritoneal cells were found to produce LAF within three 
hours. The kinetics and optimal conditions for production 
of peritoneal and splenic LAF were explored. Enhancement of 
peritoneal LAF production after LPS challenge was attained 
by pre-treating the animals with the methanol extraction 
residue of the tubercle bacillus (MER), 
The synergistic effect of murine LAF with several mito¬ 
gens, including phytohemagglutinin-P, Concanavalin A and the 
supernatant fraction from human peripheral blood leukocytes 
was demonstrated. It was also shown that dialysis of crude 
LAF preparations apparently removed an inhibitory substance. 
Preliminary data suggested that the molecular weight of 
murine LAF is 55*000 daltons and the isoelectric point is 5»°. 
Both these values are considerably different from those 
previously reported for human leukocyte LAF, but are com¬ 
parable to values determined for a murine cell line. 
» 2 
LITERATURE REVIEW 
The Role of Macrophages in the Immune Response 
Macrophages or adherent mononuclear phagocytes have an 
important accessory role in cell-mediated immunity. Both the 
adherent and non-adherent populations of murine spleen cells 
are required to produce antibody to sheep red blood cells.1 
Macrophages appear to be responsible for the uptake and 
p 
processing of antigens. Antigens bound to macrophages are 
highly immunogenic. Live peritoneal exudate macrophages, 
when transferred from an animal with exposure to a specific 
antigen to an animal which has not been exposed to that anti- 
1 4 
gen will provoke a specific immune response."® Albumin 
bound to live macrophages is approximately one thousand-fold 
more immunogenic than a comparable amount of free antigen.- 
The macrophage, however, does not appear capable of 
actually producing antibody. If stimulated macrophages are 
transferred into X-irradiated hosts"' or recipients immuno» 
logically tolerant to the antigen,^ there will be almost no 
antibody production. 
The specificity of the immune response resides with the 
7 
committed lymphocytes. The macrophages can interact with 
many antigens. However, if a specific clone of lymphocytes In 
a population of spleen cells is rendered non-functional by a 
. 





highly radioactive antigen, the immune response to that 
antigen is lost when the spleen cells are transferred to 
O 
X-irradiated mice* 
The question to be evaluated in this thesis is whether 
in a non-specific immune response (mitogenesis of thymocytes 
in the absence of antigen) the macrophage from a mouse exposed 
to antigen can be replaced by a soluble leukocyte-derived 
factor* As demonstrated below, evidence for the existence of 
such a factor has already been presented in the literature* 
The object of these studies is to determine the kinetics of 
its production in vivo and to partially purify and charac¬ 
terize the factor* 
Soluble Leukocyte-Derived Specific Lymphocyte Stimulators 
The earliest evidence that a soluble factor released 
by macrophages could be substituted for intact macrophages 
in certain immune responses came from systems which tested 
the ability of lymphocytes to respond to certain specific 
9 
antigens. In 1970 Dutton et al.y demonstrated that adherent 
mouse spleen cells restored the responsiveness of non-adherent 
spleen cells to sheep erythrocytes* They also demonstrated 
that conditioned medium manufactured by incubated adherent 
cells could restore response to this antigen® Of Interest 
was the fact that the supernatant fraction of cultured 
macrophages was effective even when the macrophages were not 
incubated in the presence of sheep erythrocytes. However, 
since the fetal bovine serum used in the medium contained 
» 
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antigens which cross reacted with sheep erythrocytes, it was 
not possible to determine from these data whether the factor 
produced by the macrophages was non-specific® Bach et al.1Q 
studied the response of purified lymphocytes to allogeneic 
lymphocytes and demonstrated the need for a soluble macrophage 
factor, which he designated CMRF (conditioned medium reconsti¬ 
tuting factor). The response was to a specific antigen and 
the macrophages were incubated in 20% plasma® Cross reacti¬ 
vity could not be ruled out® 
A Non-Specific Lymphocyte Activating Factor 
11 12 
Gery, Gershon and Waksman were the first to demon¬ 
strate that a macrophage-derived factor could stimulate 
thymus-processed (T-) lymphocytes in the absence of antigen® 
Mouse thymocytes cultured without any stimulant or in the 
presence of phytohemagglutinin-P (PHA) incorporated only a 
small amount of tritiated thymidine® However, when as few as 
6,000 human peripheral blood leukocytes were added in addition 
to PHA, a definite increase in thymidine incorporation 
occurred® When the supernatant , fraction of human leukocyte 
cultures incubated with PHA or lipopolysaccharide (LPS) was 
added to the thymocyte cultures, it resulted in a greater 
than one hundred-fold rise in the incorporation of thymidine 
by the thymocytes, both in the presence and absence of PHA. 
Syngeneic spleen cells stimulated with PHA, LPS or Goncana- 
valin A (CON A) also produced supernatant fractions which 
13 . • 
increased mouse thymocyte DNA synthesis. "■ No specific 
A ■' 
antigens had to he added to the thymocyte cultures. 
Additional experiments by Gery and Waksman1^ revealed 
that this factor, which they designated lymphocyte activating 
factor (LAF), was produced primarily, but not exclusively, by 
macrophages. They designated those cells which were adherent 
to plastic and nylon columns as macrophages, although no 
morphological data was presented. The adherent population 
of mouse spleen cells produced a conditioned medium with 
more activity than that produced by unpurified spleen cells. 
The adherent human leukocytes produced more potentiating 
factor per cell than the total leukocyte population. Although 
the adherent cell population consists primarily of macrophages, 
contamination with other cells cannot be excluded. It is 
possible that the cooperation of other cells is necessary 
for the production of LAF. 
14 
Experiments by Yoshmaga et al» demonstrated that 
peritoneal exudate cells of mice stimulated intraperitoneally 
with caseinate or the supernatant fraction derived from peri- 
toneal exudate fluid will induce DNA synthesis in mouse thymo¬ 
cytes. The peritoneal exudate cells obtained three hours after 
caseinate injection consisted of 93polymorphonuclear leuko¬ 
cytes and only 2% macrophages. At 96 hours there were 73% 
macrophages and 26% lymphocytes® Supernatant fractions from 
cultures of both the 3-hour and 96-hour exudate cells enhanced 
thymocyte DNA synthesis. The number of macrophages contained 
in the 3-hour peritoneal exudate cells (6.4 x 102 cells/cc) 
was insufficient, by itself, to produce a supernatant fraction 
• iq>. ; 
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capable of inducing mitogenesis. Although adherent cells 
definitely appear to produce LAF, other leukocytes, particu¬ 
larly polymorphonuclear leukocytes, also appear to produce 
this substance.. 
T-cell cooperation may be an important element in LAF 
13 
production, Gery and Waksman compared the production of 
LAF by cultures of mouse spleen cells with cultures of spleen 
cells from irradiated mice reconstituted with either syngeneic 
bone marrow cells or bone marrow plus thymus cells. Super¬ 
natant fractions from the PHA or CON A stimulated cultures 
obtained from the animals reconstituted with both thymus and 
bone marrow cells produced greater thymocyte response than 
the supernatant fractions from the cultures obtained from 
animals reconstituted with marrow cells alone. It would 
appear that there is a positive feedback mechanism involved 
in LAF production, in which the production of LAF by adherent 
1 5 
cells is enhanced by T cells. This was confirmed by Unanue 
et al. ^, who enhanced LAF production by peritoneal exudate 
cells from Listeria infected mice by adding in vitro the 
activated T-lymphocytes from the peritoneum of similarly 
infected animals. 
LAF is produced in vitro by cells from many species, 
including guinea pig macrophages, dog leukocytes and spleen 
and lung macrophages, as well as monkey leukocytes. However, 
under very similar conditions thymocyte stimulation was not 
produced by conditioned medium from cultures of L1210, L5178Y, 
•-'X.o £ X 
, 
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vero, BHK, HeLa or L-fibroblasts, despite the addition of LPS 
to the cell cultures.1^’ 
LAF has been produced in vivo after both acute and pro¬ 
longed stimulation. Supernatant fractions obtained from 
1-hour cultures of peritoneal exudate cells harvested 3 and 
96 hours after casein injection displayed LAF activity. Cell- 
free peritoneal exudate harvested at 3 and, 9 hours also 
14 
enhanced thymocyte mitogenesis. Mitchell et al. found LAF 
activity in the conditioned medium of 24 hour cultures of 
spleen cells from mice given the BCG strain of tubercle bacil¬ 
lus intravenously 7 to 14 days previously.1^ Gery et al. 
demonstrated enhanced production of LAF by peritoneal cells 
in animals which 7 days previously had received an intra- 
peritoneal injection of the methanol extraction residue of BCG. 
LAF production can be stimulated by a variety of sub¬ 
stances. Supernatant fractions with LAF activity have been 
obtained from human leukocytes incubated for 24 hours with 
LPS. Mitogens such as PHA and CON A promoted the release of 
LAF,1^ as did cyclic GMP.21 Irradiation in vivo increased 
the production of LAF by peritoneal exudate cells.22 Other 
investigators1^* have added latex particles, antibody- 
coated red blood cells. Listeria organisms and beryllium salt 
in vitro to peritoneal exudate cell cultures and found that 
these substances increase the production of a factor capable 
of interacting with macrophages and producing enzymatic and 
morphological changes. However, Unanue's group did not find 
vo b C D 
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a direct relationship between morphologic changes in the macro- 
phage and the secretion of lymphostimulatory material* Gery 
ok 
et al® found that LAF production by peritoneal cells 
activated either in vitro or in vivo did not necessarily 
correlate with the secretion of lysosomal enzymes. 
There is evidence for the existence of macrophage products 
which both stimulate and inhibit lymphocytes*2^ It is 
important to note that several authors have found a soluble 
macrophage product which inhibits thymidine incorporation by 
lymphocytes stimulated with PHA.2^"2^ Opitz and his group^0 
studied this suppressor and found that it merely reduced 
thymidine incorporation without inhibiting DNA synthesis as 
measured by cell proliferation* Inhibition was temporary and 
ceased when the substance was washed out. The suppressing 
factor was dialyzable and heat stable® The most attractive 
explanation was that the macrophages were releasing thymidine, 
which diluted the radioactively labelled thymidine. Macro¬ 
phages cultured with T-lymphocytes present on the opposite side 
of a separation chamber did not produce the inhibitor of 
thymidine uptake, and Opitz et al« postulated that macrophages 
phagocytize and degrade dead lymphocytes and subsequently 
release degradation products, including thymidine, into the 
medium. 
LAF obtained from human leukocytes and mouse peritoneal 
cell cultures stimulated with endotoxin has been purified and 




and it could be precipitated by ammonium sulfate. Sephadex 
chromatography localized activity in fractions containing 
molecules ranging in weight from 5,000 to 25,000 dal.tons 
with a peak of activity at 15*000.^2 Calderon et al» 
described a molecule with similar stimulatory activity and 
a molecular weight of between 15*000 and 21,000 daltons. The 
molecule was not sensitive to diisopropylfluorophosphate 
treatment, but was sensitive to chymotrypsin and pepsin. The 
"’enhancing factor" discussed by Nakamura et al. ^ was prepared 
from polymorphonuclear leukocytes in the mouse peritoneal 
exudate. It was also capable of potentiating DNA synthesis 
by syngeneic thymocytes stimulated with PHA. This factor had 
a molecular weight of 19*000, was non-dialyzable, heat labile 
and stable in solutions with a pH ranging between 3 and 9« 
In addition, the LAF activity was associated with a proteo¬ 
lytic activity on 3H-aeetyi hemoglobin. Both the thymocyte 
stimulating effect and the proteolytic effect were abolished 
by Trasylol, a protease inhibitor. Since two leukocyte 
products could elute in the same Sephadex fraction, these 
findings do not prove that the molecules are identical. 
35 
Lachman et aJU presented evidence that LAF from a murine 
peritoneal cell line P388-DI has a much higher molecular 
weight (80,000 daltons). 
Enhancement of Immune Responsiveness and Its Possible Role 
in Tumor Immunotherapy 







noted that some malignant tumors appeared to regress coinci¬ 
dentally with the occurrence of erysipelas®-''' Fifty years 
ago Coley treated cancer patients with bacterial culture 
fluids (Coley’s toxin), which contained endotoxin among 
other cellular products® He achieved striking tumor regression 
in some of his patients®3? Although the mechanism by which 
these agents might have acted is unclear, the results provided 
impetus for scientists to study immune enhancement as a means 
of cancer therapy® 
BCG Immunotherapy 
Recently a modified strain of the tubercle bacillus, 
(Bacillus Calmette-Guerin or BCG) has been investigated in 
humans as an adjuvant to surgery and conventional cancer 
chemotherapy®38* 39 Many investigators have demonstrated a 
response to BCG in animal tumors, particularly those induced 
by carcinogens and a mouse lymphoid leukemia line®^®"^4" 
The mechanism of action of BCG, endotoxin and other 
immunetherapeutic agents is not completely understood, but 
clues have been emerging® Mitchell et al®~ reported 
increased cell-mediated immunity in mice inoculated with 
BCG® Spleen cells from these animals had increased capa¬ 
city to lyse tumor cells® Also the spleen cells from BCG- 
treated animals produced more of the lymphocyte activating 
factor, as demonstrated by the ability of supernatant fluid 
from the splenocytes to increase syngeneic thymocyte DNA 
incorporation® The adherent spleen cells from the treated 
* 
f. ' * 
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animals produced 3 to 3s times the LAF activity of the normal 
mouse adherent spleen cells® 
The human melanoma appears to be an ideal tumor for 
immunetherapy, since it is capable of causing an immune 
response® Nagel et al.^5 observed specifically sensitized 
lymphocytes in an individual who had recently undergone 
46 
surgery for malignant melanoma® Bodurtha et al. found a 
complement dependent cytotoxic antibody to autochthonous 
tumor cells in the serum of nine of ten patients with local¬ 
ized or regionalized melanoma and in only one of eleven 
patients with disseminated metastases® 
Endotoxin, the Immune Response and Tumor Immunotherapy 
Endotoxin or lipopolysaccharide (LPS) from gram negative 
bacteria has been utilized to stimulate an immune response 
and render macrophages cytotoxic® In certain situations 
endotoxin has been used successfully to cause tumor necrosis 
and increase mouse resistance to tumor® 
The immune response to LPS appears to involve primarily 
B-lymphocytes and macrophages®^? Both athymic (nude) mice 
and their normal littermates respond in the same primary and 
secondary fashion to LPS. This was not the case for the 
response to equine erythrocytes® The immune response to this 
agent was severely impaired in the athymic mice® Both an 
antibody response and a specific plaque forming cell response 
can be demonstrated after an intraperitoneal or Intravenous 
injection of LPS. A primary effect can be demonstrated after 
* 
12 
the injection of as little as 10“3 Ug 0f LP8, 
48 
Alexander and Evans demonstrated that endotoxin as well 
as double-stranded RNA could "activate" mouse macrophages and 
provide them with the capability of killing mouse lymphoma 
cells. A macrophage preparation obtained from peritoneal 
cells was unable to inhibit the growth of lymphoma cells 
unless the macrophages had been exposed to endotoxin for at 
least thirty minutes. These "activated" macrophages differed 
from "stimulated" peritoneal macrophages, which resulted from 
intraperitoneal injection of BCG or thioglycollate• Stimulated 
macrophages contained an increased number of lysosomes but 
were incapable of inhibiting the growth of lymphoma cells. 
Currie and Basham^ reported that cellular apposition was 
not a prerequisite for macrophage toxicity and that a stable 
supernatant product was capable of lysing tumor cells. 
Several derivatives of endotoxin appear to have anti¬ 
tumor activity. A group in Japan^0? 51 found a protein 
fraction of endotoxin from Pseudomonas aeruginosa was capable 
of inhibiting the growth of ascites sarcoma 180, while the 
/ 
intact LPS from these bacteria was ineffective. Nowotny, 
Golub and Key^2 demonstrated that the complete endotoxin, the 
non-toxic endotoxoid (prepared from endotoxin by deacylation 
with potassium methylate) and endotoxin glycolipids all were 
capable of producing hemorrhagic necrosis in tumors. 
The literature is replete with demonstrations of the 
effectiveness of endotoxin in inhibiting tumor growth. 
■ . "<Si b %y 




Several mechanisms appear to be operational: hemorrhagic 
necrosis, enhancement of tumor antigenicity by endotoxin 
coating of tumor cells, and generalized enhancement of the 
immune recognition system* 
Parr, Wheeler and Alexander^ studied several variables 
related to hemorrhagic necrosis. Treatment with endotoxin 
or double-stranded RNA was effective against subcutaneous or 
intradermal tumors, but had no effect on intraperitoneal 
tumors. Unless the tumor was "established" (had been implanted 
for seven days), endotoxin was not effective. The authors 
demonstrated that several host factors contributed to tumor 
regression. Vascular hemorrhage had to occur and this could 
be blocked by heparin. Immunosuppression by whole body 
irradiation or anti-lymphocyte serum also interfered with tumor 
regression, despite the fact that hemorrhage still occurred. 
Tumor antigenicity (the number of cells rejected after immuni¬ 
zation with irradiated tumor cells) correlated with the magni¬ 
tude of anti-tumor activity of systemically introduced endotoxin 
against specific tumors,^ Based on these results, it would 
appear that both vascular damage, which permits the endotoxin 
and various cellular elements and products to gain access to 
the tumor, and activation of an immune response are required, 
A serum factor has been isolated which appears to mediate 
hemorrhagic necrosis and mimics endotoxin in this effect. 
It can be produced by administering endotoxin intravenously to 
mice which had received BCG two weeks previously. The tumor 
* 
, 
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necrosis factor is not residual endotoxin. This glycoprotein 
has a molecular weight of 150,000 dal tons and migrates with 
the c*-globulins. The BCG appears to "activate” macrophages 
and produces an increase in lysosomes. The macrophages 
apparently become extremely sensitive to endotoxin, which 
releases the macrophage contents by disruption. ^-)9 
Two groups produced tumor rejection by administering 
tumor cells or modified tumor cells in the presence of endo- 
I'ty r Q 
toxin®" * The endotoxin had no apparent direct toxic 
effect on the tumor cells, but rather appeared to cause a 
localised stimulation of host resistance, perhaps by coating 
the tumor cells and making them more immunogenic. The animals 
were able to resist a lethal dose of tumor cells administered 
after the simultaneous administration of tumor and endotoxin® 
This response was not obtained when only modified tumor cells 
or only endotoxin was given prior to the lethal dose challenge 
Bober and her group-59 found intraperitoneal injection of 
small amounts (0.1 to 0.5 ug) of endotoxin protected mice 
against a challenge of a mineral oil induced plasma cell 
tumor. Endotoxin treatment before and after tumor injection 
provided the best protection and this effect was seen with 
both intraperitoneally and subcutaneously injected tumor. 
Mice injected with the TA3-Ha mouse ascites cell line 
were able to suppress tumor growth when immunized with a 
small amount (10 ug) of endotoxin prior to tumor challenge•* 6i 
The TA3-Ha tumor line is one which lost strain specificity but 
' 
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which retained major histocompatibility antigens* Sensitiza- 
tion of allogeneic mice with skin grafts from strain A mice 
in which the tumor originated caused the recipient mice to 
become relatively tumor resistant® Stimulation of the host 
immune system by the intraperitoneal injection of 10 ug of 
endotoxin 3 to 0 days prior to tumor inoculation was 
sufficient to enable the host to destroy a lethal tumor dose® 
The endotoxin did not have a direct cytotoxic effect on tumor 
cells® Protection against tumor could be adoptively trans¬ 
ferred by normal spleen cells exposed in vivo and in vitro 
to endotoxin® These experiments support the use of generalized 
enhancement of the immune response and host resistance as a 
means of controlling tumor growth and suggest that this 
approach should be especially successful against tumors with 
a high degree of antigenicity® 
J, 
materials and methods 
Animals 
B6D2F1 mice obtained from Cumberland Farms were used for 
all experiments unless otherwise noted® Upon arrival the 
animals weighed 18 to 20 grams and were approximately 6 
weeks old® The mice were given a one week course of strepto¬ 
mycin in the drinking water (40 ug/cc) and completed treat¬ 
ment at least one week prior to the experiments. The animals 
were fed Purina Lab Chow® At the time of the experiments the 
mice were 3s to 5 months of age and weighed 30+3 grams® GDI 
mice (Cumberland Farms, age 18 weeks, average weight 45 grams) 
and C3H mice (Charles River Laboratories, age 1? weeks, 
average weight 2? grams) were used in one experiment® 
Thymus cells for the lymphocyte activating factor (LAF) 
assay (see below) were obtained from GDI mice age 8 to 10 
weeks® 
Reagents 
Lipopolysaccharide B from Escherishia coli strain 055*B5 
(LPS, Difco Laboratories, Detroit, MI, Lot 611788) was used® 
Suspensions were prepared in 0.9% sterile saline, and the 
required dosage was contained In 0®2 cc of saline® 
The methanol extraction residue of Bacillus Calmette-Guerin 
. •' > 
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(Phipps strain) or MER was a gift of the National Cancer 
Institute® The preparation used. Lot BV 73-240, contained 
MER in a concentration of 2 mg/cc, sodium chloride (9 mg/cc), 
sodium carboxymethyl cellulose (5 mg/cc) and polysorbate 80 
(0.004 cc/cc) in sterile wafer. In some experiments the 
mice received 0®5 cc (1 mg) of MER intraperitoneally 5 days 
prior to receiving an intraperitoneal injection of 50 ug of 
LPS, 
All injections were done intraparitoneally using a #26 
gauge disposable needle and a 1 cc or 5 cc Plasti-pak syringe 
(Becton-Dickenson, Rutherford, NJ). 
Recovery of %-LPS from Peritoneal Washings 
Tritiated LPS was prepared by New England Nuclear 
(0.166 mC/mgj, special order #84l-269“29?7) by exposing 190 mg 
of EH coli LPS to 3 curies of tritium at 24°c for 2 weeks 
and lypholyzing the product 4 times. Twelve mice received 
an intraperitoneal injection of a mixture containing 10 ug 
of tritiated LPS and 90 ug of non-radioactive LPS in 0.2 cc 
of normal saline. Immediately following Injection, 6 animals 
were sacrificed and 6 animals were killed 4 hours after the 
injection. Three cc of Minimal Essential Medium with Earle's 
salts (MEM, Grand Island Biological Company, Grand Island, 
NY) supplemented with glutamine (2 mM), penicillin (1000 
U/liter), streptomycin (1000 ug/liter) and 0.05 M HEPES 
(Calbiochem, La Jolla, CA) at pH 7*4 was injected intraperi¬ 





gently agitated® (Note; Throughout the remainder of this 
report MEM will refer to the supplemented MEM just described.) 
Two cc (+10°/o) of fluid was aspirated back and centrifuged at 
500 g for 15 minutes® The supernatant fraction was decanted, 
added to 2 cc of scintillation fluid (described below), and 
counted in a liquid scintillation counter for 1 minute. 
Production of Lymphocyte Activating Factor (LAF) 
Peritoneal washings that contained lymphocyte activating 
factor (LAF) were prepared by injecting B6D2F1, GDI and G3H 
mice intraperitoneally with various dosages of lipopoly- 
saccharide (LPS). At a specified time period after the LPS 
injection the mice were sacrificed by cervical dislocation® 
The skin and abdominal muscles were incised to expose the 
peritoneum. Three cc of MEM was injected intraperitoneally 
and the peritoneum was gently agitated. Approximately 2 cc 
of fluid was aspirated back using the same needle® The 
fluid was centrifuged at 5GQ g for 10 minutes and the super¬ 
natant fraction was sterile filtered through a 45 n Millipore 
filter (Swinnex 0.45 13 mmj Millipore Corporation). 
Samples were either assayed immediately or frozen at -4°C 
following the addition of human serum (Grand Island Biolo¬ 
gical Company, Lot 4030068) equivalent to 5$ of sample 
volume® 
Splenic LAF was piroduced by injecting various strains 
of mice with LPS in the manner described above® The animals 
were sacrificed and the spleens were removed. The spleens 
» 
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were placed in 5 cc of MEM and homogenized individually by 
hand with a Potter Elvejehm homogenizer with a Teflon pestle 
(McAllister Bicknell Co.}, The spleen cells were then cultured 
at various concentrations and for various periods of time in 
15 x 100 mm plastic Petri dishes (Fsilcon Plastics, #1029, 
Oxnard, CA). Plates we re incubated at 3?°C with 5% C02- 
After 0 to 28 hours the plates were removed from the incubator 
and the suspension was centrifuged at 500 g for 10 min. The 
supernatant fraction was decanted and sterile filtered. The 
filtrate was either assayed immediately or treated with 
serum (5$ v/v) and frozen. 
In some experiments various substances were added to 
the splenocyte cultures. These included LPS, human AB+ donor 
plasma (Mew York. City Red Cross Blood Bank), and isogeneic 
thymocytes. The thymocytes were prepared by removing 
the thymuses from B6D2F1 mice and homogenizing them in 5 cc 
of MEM, as described previously. The thymocytes were 
counted in a hemacytometer and diluted with MEM to a concen- 
7 
tration of 1 x 10' cells per cc. One cc of this suspension 
ft 
was then added to a suspension containing 5 x 10° splenocytes 
per cc. The final thymocyte concentration was 1 x 10^ cells/cc. 
The LAF Assay 
The standard LAF assay initially developed by Gery, 
Gershon and Waksman^ and modified by Blyden and Handschumacber1® 




substance to promote thymidine incorporation in a population 
of thymus cells. Thymuses were removed from 8 to 10 week GDI 
mice and homogenized individually in MEM with a Potter Elvejehm 
homogenizer with a Teflon pestle® The thymocytes were pooled 
and their concentration determined in a hemacytometer* The 
/■ 
concentration was adjusted to 5 x 10° cells per cc by dilution 
with MEM. Human serum was added to this suspension to a 
final concentration of 5% (v/v), and 2-mereaptoethanol was 
added to a final concentration of 0*05 mM. One cc aliquots 
of this suspension were pipetted into the cylindrical wells 
on a plastic plate (Linbro Scientific Co., Hamden, CT, catalog 
#FBl6-24TC). Into each well was added 0.1 cc of the solution 
being tested for LAF activity. Into selected wells either 
PHA (Phytohemagglutinin-P, Difco Laboratories; final concen¬ 
tration of 50 ug/cc), CON A (Concanavalin A, Calbiochem, 
2.5 ug/cc) or 0.1 cc of the supernatant fraction from LPS~ 
stimulated cultured human peripheral blood leukocytes was 
added. The plates were incubated at 37°C with 5% CO2® After 
48 hours 1 uCi of tritiated thymidine (1.9 uCi/mM; New England 
Nuclear) in 0.1 cc of normal saline was added. The plates 
were then incubated for an additional 24 hours. The contents 
of the wells were harvested on a 24 sample manifold using 
glass fiber gilter paper (Whatman, Inc., Clifton, NJ; catalog 
#934AH) soaked in 1 mM thymidine. The filter paper was then 
washed with saline and 5% trichloroacetic acid and allowed to 




containing 2 cc of scintillation fluid (prepared from 3*8 1. 
toluene, 19 gm 2, 5-diphenyloxazole, O.95O gm p-bis £2-(5 phe- 
nyloxazolyl benzene]] ) and counted for 1 minute in a liquid 
scintillation counter. 
All samples were assayed in triplicate, and the results 
reported are the means + standard error. 
Purification and Characterization of LAF 
LAF was partially purified by eliminating certain 
dialyzable inhibitory products® Two to three cc of crude 
LAF preparation was placed in a length of dialysis tubing and 
allowed to stand overnight (12 to 18 hours) in 2 1. of pH ?»4 
HEPES-saline solution (0.05 M HEPES + 0.9% saline). The 
non-dialyzable fraction was sterile filtered with a 45 u 
Millipore filter prior to assay. 
LAF was concentrated using an Amicon ultrafiltration unit 
(Model 52) with a UM-10 membrane (nominal retention - 10,000 
daltons). Forty cc. of crude splenic or peritoneal LAF was 
concentrated to 10 cc® These concentrates were used in the 
molecular weight and isoelectric point determinations outlined 
below® 
Sephadex G-150 gel (Pharmacia) was prepared by boiling for 
5 hours in 0.04 M HEPES-0.15 M sodium chloride buffer, pH ?®5® 
The gel was poured into 25 x 0*5 cm columns and equilibrated 
with the same buffer. Columns were standardized with globulin, 
albumin and cytochrome C. The four-fold concentrated samples 
(1.25 cc aliquots) were placed on top of the columns and eluted 
* 
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with the HEPES-chloride buffer. One cc samples were collected 
for assay. 
Isoelectric focusing was performed on an LKB Model 8100 
apparatus (Produkter, Sweden) with a 110 cc column containing 
Ampholines with pH ranging from 3 to 10® Eight cc of concen¬ 
trated LAF preparation was added to the column, and after 36 
hours of focusing, 4 cc fractions were collected and the pH 
of each sample was measured. The samples were dialyzed 
against two changes of the HEPES-chloride buffer and sterile 




Production of LAF in the Peritoneum 
Within the peritoneum, the response to intraperitoneally 
injected lipopolysaccharide (LPS) is relatively rapid* 
Analysis of the supernatant fraction of peritoneal washings 
revealed a peak of mitogenic activity at 3 hours in the 
absence of additional mitogens in the assay and at 6 hours 
in the presence of either PHA or the supernatant fraction 
from human peripheral blood leukocytes stimulated with LPS 
(See Figure I)* Activity returned to base line values or 
less by 24 hours* It is interesting to note that the addi¬ 
tion to the assay wells of cell-free peritoneal exudate from 
mice receiving 0.2 cc of normal saline intraperitoneally 
resulted in a decrease in the incorporation of tritiated 
thymidine by the thymocytes* This was also true for all 
samples from LPS treated mice, except for the 3 and 6 hour 
samples * 
There was a definite relationship between the intraperi- 
toneal dose of LPS and the mitogenic activity of the peri¬ 
toneal washings (See Figure II)* Two out of three mice that 
received 500 ug of LPS intraperitoneally died within 48 hours, 
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FIGURE I--TIME COURSE OF LAF PRODUCTION IN THE SUPER¬ 
NATANT FRACTION OF PERITONEAL EXUDATE--B6D2FI mice received 
50 jug of LPS intraperitoneally at Time = 0 and were sacrificed 
after various Intervals* The cell-free peritoneal exudate 
was tested for its ability to enhance thymocyte mitogenesis 
alone (O), in the presence of PHA (A), and in the presence of 
the supernatant fraction of LPS-stimulated human peripheral 
blood leukocytes (HUMAN SUP,D). Control mice received 
0*2 cc of normal saline intraperitoneally* Cell free peri¬ 
toneal exudate from these mice was assayed alone (#), with 
PHA (A) 1 and with HUMAN SUP (H). Tritiated thymidine (3H-TdR) 
incorporation was 617+88 for thymocytes without a mitogen, 
888+20 for thymocytes and PHA and 20,745+1,423 for thymocytes 




FIGURE II—RELATIONSHIP BETWEEN INTRAPERITONEAL LPS DOSE 
AND LAF PRODUCTION IN THE CELL-FREE PERITONEAL EXUDATE— 
Mice received various intraperitoneal doses of LPS suspended 
in 0.2 cc of normal saline. The animals were sacrificed 
after 4 hours. The supernatant fraction of the peritoneal 
exudate was assayed alone (®), in the presence of PHA (a), 
and in the presence of the supernatant fraction of LPS- 
stimulated human peripheral blood leukocytes (HUMAN SUP,® ). 
Tritiated thymidine (^H-TdR) incorporation was 1578+280 for 
thymocytes without added mitogen, 1871+101 for thymocytes and 
PHA, and 19,180+1,873 for thymocytes and HUMAN SUP. All are mean 
values are + standard error of 3 determinations. 
/ 
26 
Mice given 100 ug of LPS were severely ill with diarrhea and 
diminished activity. 
Injection with the methanol extraction residue of BCG 
(MEF.) also resulted in enhanced activity in the supernatant 
fraction of the peritoneal washings. Xntraperltoneal MER 
Injection did not by itself result in increased supernatant 
fraction activity after five days. However, in mice given 
a sub-optimal intraperitoneal dose of LPS (50 ug) five days 
after receiving 1 mg of MER there was a marked rise in 
activity in the peritoneal washings four hours after the 
LPS injection. There was no detectable LAF activity in the 
mice that had received an Injection of saline 5 days before 
the LPS challange-(See Table I.). 
Studies using radioactively labelled LPS revealed that 
this substance is cleared rapidly from the peritoneum. Four 
hours after intraperitoneal injection only 0.15% of the 
initial dose was recovered. This can be compared to the 
10.1% recovery Immediately following Injection. The 
addition of 0.1, 1, 10, and 25 ug of LPS to the assay wells 
in various experiments did not result in mitogenic activity 
significantly different from that of the control. 
Splenic LAF 
Spleen cells from mice stimulated with LPS were capable 
of releasing LAF when the cells were removed and cultured in 
medium without serum. To determine the time response curve 
for LAF production, spleens were excised at various intervals 
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TABLE I 
ENHANCEMENT OF LPS INDUCED LAF PRODUCTION 
BY TREATMENT WITH METHANOL EXTRACTION RESIDUE OF BCG (MER) 
^H-TdR Incorporat ion (CPM) 
Treatment 







MER—Img LPS-50ug 3511+244 7200+604 43634+3887 
MER-lmg Saline 2 ? 8+ 31 483+ 21 31043+1863 
Saline LPS-50ug 490+ 76 636+ 63 22155+1202 
Saline Saline 187+ 15 483+ 26 26392+ 572 




Mice received either 1 mg of MER or 1 cc of normal 
saline intraperitoneally on day 0 and 50 ug of LPS or 0.2 cc 
of normal saline intraperitoneally on day 5* Four hours 
after the second injection the mice were sacrificed and a 
supernatant fraction of the peritoneal exudate prepared. 
All values reported are the mean of three determinations 
4- standard error. 
: i. Cb i- - 
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incubator for a fixed interval (See Figure III), When all sam¬ 
ples were dialyzed against HEPES buffer prior to assay, a. 
biphasic activity curve resulted. There was a peak of production 
at 3 hours and a secondary rise In activity at 24 hours. (These 
times are the interval between LPS injection and the removal 
of the spleen from the animal® They do not include the 6 hour 
incubation period.) 
The optimal incubation conditions were also determined® 
(See Figure IV.) The maximal rate of LAF release appeared to 
occur during the l| hours between the injection of LPS and the 
removal of the spleen from the mouse® (Compare the values at 
time 0 for the supernatant fractions from mice that had received 
LPS and saline with values obtained from supernatant fractions 
of spleen cells cultured for various lengths of time® To obtain 
time 0 values the spleen cell homogenate was centrifuged immedi¬ 
ately and the supernatant promptly frozen.) A peak of activity 
occurred at 22 hours among the dialyzed samples® The mitogenic 
potential of the undialyzed samples was relatively constant® 
At l'| and 4 hours the ratio of mitogenic activity of dialyzed 
to undialyzed samples assayed in the presence of PHA or CON A 
was 10-1*6. However, at 22 hours this ratio was 2®3» LAF 
release was also a function of cell concentration in vitro® At 
higher cell concentrations (2 x 10? cells/cc) less LAF activity 
per spleen cell was produced (See Table II). 
Several unsuccessful attempts were made to stimulate LAF 
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FIGURE III—LAF PRODUCTION BY DIALYZED SUPERNATANT FRACTIONS 
OF SPLEEN CELLS HARVESTED AT VARIOUS INTERVALS AFTER LPS 
INJBCTI0N--Mice received 100 ug of LPS intraperitoneally 
and were sacrificed at various intervals after the injection. 
Spleen cells were incubated in MEM (without serum) for 6 hours 
at a concentration of 3.5 x 10? cells/cc. The dialyzed supernatant 
fractions of the cultures were assayed in the absence of 
additional mitogens («), with PHA (A) or with CON A (■). 
Spleen cells from mice given 0.2 cc of normal saline intra¬ 
peritoneally were harvested after li hours and cultured for 
6 hours. Initiated thymidine (3H-TdR) incorporation was 
4551.26 for the supernatant fraction from these cells, 2?43+198 
for this fraction and PHA and l4,556+3?4 for this fraction and 
CON A. Values for the control assay were 1225+224 for the 
thymocytes withi^t any mitogens, 1192+352 for the thymocytes 
and PHA, and 9850+1078 for the thymocytes and CON A. All 
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FIGURE IV--LAF PRODUCTION BY CULTURED SPLEEN CELLS EXPOSED 
TO LPS IN VIVO--DIALYZED VS. UNDIALYZED SUPERNATANT 
FRACTIONS--Mice received 100 ug LPS intraperitoneally 
and were sacrificed l| hours later. The spleens were homo¬ 
genized and 'cell concentration adjusted to 2 x 10^ cells/cc. The 
cells were incubated in MEM (without seum) for various lengths 
of time. Samples were dialyzed against HEPES and assayed in 
the presence of PHA (A) or CON A (P). Undialyzed samples were 
also assayed with PHA (A) or CON A (®). A group of mice 
received 0.2 cc of normal saline instead of the LPS. Super¬ 
natant fractions were prepared as described above and assayed 
with PHA (SA) or CON A (SP). Tritiated thymidine (3H-TdR) 
incorporation was 1468+366 for the thymocytes without any mito¬ 
gen, 1198+255 for thymocytes and PHA, and 10,800+1121 for 
thymocytes and CON A. All values are the mean of three detr- 






EFFECT OF SPLEEN CELL CONCENTRATION 
IN VITRO ON LAF PRODUCTION 










+C0N A (2.5ug) 
LPS-lOOug 5 X 105 806+10? 649+120 1923+189 
LPS-lOOug 5 X 106 577+231 1812+288 4225+310 
LPS-lOOug 2 X 10? 579+ 37 5541+181? 7555+391 
Saline 5 X lo5 629+ 30 752+ 93 1572+327 
Saline 3 X 106 893+590 926+ 16 1423+6?? 
Saline 2 X 10? 398+ 73 660+ 4? 1005+327 
No Spleen Sup, . Added 689+262 936+164 
(PHA only) 
1649+154 
(CON A only) 
Mice received 100 ug of LPS or 0,2 cc of saline intra- 
peritoneally and were sacrificed It hours later. The spleens 
were homogenized and the cell concentration was adjusted with 
MEM (without serum). Spleen cells were incubated for 6 hours, 
and the supernatant fraction was obtained and assayed® All 




addition to unstimulated spleen cells of 2 ug/cc or 20 ug/cc 
of LPS, 1 x 10? thymocytes, 0.05 cc/cc of human plasma or 
various combinations of these agents failed to cause LAF 
production. 
Although the majority of the studies employed GDI thymo¬ 
cytes in the assay of LAF produced by B6D2F1 mice, the allogenic 
nature of the source of LAF and its assay target was not 
essential for the demonstration of LAF activity. LPS stimulated 
spleen cells from GDI and C3H mice produced LAF activity 
similar in magnitude (+25%) to that produced by B6D2F1 spleno- 
cytes (See Table III). GDI thymocytes were used in the assay 
culture, the dose of LPS was adjusted to the weight of the mouse 
(3 ug LPS/gm mouse), and in vitro cell concentration and incu¬ 
bation time were held constant. 
The direct addition of GDI, B6D2F1 or C3H spleen cells 
exposed in vivo to LPS to the GDI thymocytes in the assay 
wells resulted in total thymidine incorporation greater than 
the algebraic sum of the thymidine incorporation by either 
cell type alone (See Table IV). In the presence of CON A 
the synergistic effect was also seen with unstimulated 
splenocytes and thymocytes® In other experiments (See 
Tables II and III) the conditioned medium from unstimulated 
splenocytes did not promote mitogenesis of thymocytes, and 
in some cases it was slightly inhibitory. 
Characterization of Murine LAF 




PRODUCTION OF SPLEEN CELL LAF 
IN DIFFERENT STRAINS OF MICE 













LPS (lOOug) B6D2F1 386+ ?8 1102+159 9767+663 
LPS (lOOug) GDI 6ll+ 13 1323+245 12058+471 
LPS (lOOug) C3H 1096+322 917+114 7464+647 
Saline B6D2F1 987+472 493+ 60 3478+213 
Saline GDI 486+189 890+208 3603+178 
Saline C3H 876+156 1092+230 3500+418 
No Spleen Sup. Added 1130+277 H66+333 
(PHA only) 
4779+686 
(CON A only) 
Mice received 100 ug of LPS or 0,2 cc of saline IP and were 
sacrificed l| hrs after the injection* The spllen cells were 
cultured for 5 hrs at a concentration of 1.2 x 10® cells/cc. 
The undialyzed supernatant fractions were assayed. All values 
reported are the mean of three determinations + standard error* 
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chromatography suggests that peritoneal LAF has a molecular 
weight of 55*000 daltons (single determination of the ability 
of various fractions from the column to enhance thymocyte 
mitogenesis in the presence of CON A), There was a secondary 
peak of activity at 13,000 daltons (See Figure V •). 
Splenic LAF appeared to have a molecular weight of 
55*000 + 15*000 daltons (two determinations-- See Figure VI ,). 
In one experiment there was a secondary peak of activity cor¬ 
responding to a molecular weight of 180,000, 
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FIGURE _y--G-150 SEPHADEX COLUMN CHROMATOGRAPHY OF PERITONEAL LAF 
Peritoneal LAF was prepared by injecting 100 ug of LPS 
mtraperi.tonea.lly into B6D2F1 mice. The mice were sacrificed 
3 hrs after the injection and the peritoneums washed with 3.5 
cc of MEM. The supernatant fraction was obtained and concen¬ 
trated by a factor of 4. An aliquot (1.25 cc) was placed on 
^°P of a25 x 0.5 cm Sephadex G-150 column and eluted with 
HEPES buffer. Each 1.0 cc fraction was assayed with 2.5 ug of 
CON A. Initiated thymidine (3H-TdR) incorporation for the 
thymocytes and CON A alone (X) was 42,308+9,667. All values 




FIGURE VI--G-150 SEPHADEX COLUMN CHROMATOGRAPHY OF SPLENIC LAF 
Splenic LAF was prepared by Injecting 100 ug of LPS 
intraperitoneally into B6D2F1 mice* The mice were sacrificed 
after lk hours and the spleens removed and homogenized* The 
spleen cells were incubated for 2 hours at 37°C, and the super¬ 
natant fraction was obtained and concentrated by a factor of 
4, An aliquot (1.25 cc) was placed on top of a 25 x 0.5 cm 
Sephadex G-150 column and eluted with HEPES buffer. Each 1.0 
cc fraction was assayed with 2.5 ug of CON A and tritiated 
thymidine (3H-TdR) incorporation by GDI thymocytes was measured. 
All values represent the mean of three determinations. 
I 
DISCUSSION 
These data confirmed the work of previous investigators, 
who demonstrated the production by leukocytes of a soluble 
factor, which is capable of enhancing lymphocyte mitogenesis. 
These experiments furthered this work by delineating an 
in vivo system in which LPS rapidly produced LAF within the 
peritoneum and spleen* 
Peritoneal. LAF 
The rapid accumulation of LAF within the peritoneum of 
mice following the intraperitoneal injection of LPS is con- 
sistent with the results obtained by Yoshinaga e_t al. They 
demonstrated that cell free peritoneal exudate caused maximal 
enhancement of thymocyte DNA synthesis when harvested 3 or 9 
hours after the intraperitoneal injection of casein. Unfor¬ 
tunately, these cell-free peritoneal exudates were not 
dialyzed. If is possible that the release of thymidine by 
inflammatory cells interfered with the assay, which measured 
the incorporation of radioactively labelled thymidine by 
thymocytes. If a large amount of unlabelled thymidine 
were present during the assay, the measured rate of DNA 




The rapid production of LAF following challenge with an 
inflammatory agent raises a question regarding the cellular 
origin of LAF* During the first 24 hours of inflammation the 
1 u 
predominant cell is the polymorphonuclear leukocyte. Only 
after 3 days does the macrophage predominate. Yoshinaga et 
ali^measured the direct enhancing effect of peritoneal exudate 
cells on DNA synthesis by thymocytes stimulated with PHA (both 
cell types plus PHA in the same well). They found that early 
exudates (93% polymorphonuclear leukocytes and 2% macrophages) 
had a greater enhancing effect on DNA synthesis than the 96 
hour exudate which contained 73% macrophages. An earlier 
report by Gery and Waksman J indicated that LAF was produced 
almost entirely by the plastic-adherent cell population 
(presumably macrophages). These data suggest that other- 
leukocytes can produce LAF, although it is possible that, the 
small number of macrophages present initially could have 
produced a large quantity of LAF. 
Very large doses of LPS (50 jug per mouse or 2 ug/gm) 
were required to cause the appearance of LAF activity in the 
cell-free peritoneal exudate. The 100 jag dose used in most 
experiments caused the animals to become very ill and 
500 ug was a dose greater than the LD^q» Some researchers 
have demonstrated that very small doses of LPS (<1 ug per 
mouse) inhibit the growth of certain tumors®^* ' 
Although it is possible that such small doses of LPS had a 
slight effect on LAF production, this was undetectable by 




The intraperitoneal injection of MER 5 days before the 
LPS challenge resulted in greatly increased LAF production 
within the peritoneum. However, MER alone did not produce an 
increase in LAF production. The peritoneum in the normal 
mouse contains few macrophages or polymorphonuclear leuko¬ 
cytes , but during inflammation the number of cells increases® 
The chronic inflammation may also enhance the ability of LPS 
to release LAF by stimulating the formation and storage of 
LAF. It can be hypothesized that the injection of LPS into 
the already inflamed peritoneum provokes the rapid release of 
LAF* which has been manufactured in response to MER. In 
20 
contrast, Gery et al. have demonstrated that peritoneal- 
exudate cells will release more LAF in culture when they are 
removed from a mouse that has been treated with MER than when 
they are derived from an unstimulated animal, and that no 
further stimulation is required® 
Splenic LAF 
Rapid production of LAF also occurred in splenocytes® 
Within 3 hours (!§- hours between injection and the start of 
incubation and l| hours of incubation with medium) signifi¬ 
cant activity was already present® The earliest activity 
noted by Blyden and Handschumacher^-® in the conditioned 
medium from in vitro stimulated human peripheral blood 
leukocytes occurred after 6 hours. The processing of LPS 
and stimulation of LAF production appear to be faster when 
the LPS is presented to the cells in an in vivo system. 

Previous reports from this laboratory1® have suggested 
that LAF is produced by leukocytes and not merely released* 
When unstimulated leukocytes were lysed osmotically and the 
supernatant fraction cultured with LPS for 24 hours, the 
activity was less than 10% that of intact leukocytes® This 
also suggests that the activity is not simply a degradation 
product of LPS* but it does not rule out the possiblity 
that LAF is the product of a larger precursor molecule* 
whose enzymatic breakdown is stimulated by LPS® 
The biphasic production of LAF could be interpreted in 
several ways® There could be a precursor molecule available 
for rapid conversion or there could be rapid peptide syntesis® 
The secondary peak seen at 24 hours may reflect adaptation by 
the cell via enhanced protein synthesis® It is also possible 
that different cell types (polymorphonuclear leukocytes and 
macrophages) produce LAF at different times® In interpreting 
these data caution must be employed, since the amount of LAF 
activity represents the algebraic sum of the production and 
breakdown of LAF in the system® The lower value at 9 hours 
could simply be the result of the breakdown of the large 
amount of LAF produced within the first 2 hours® 
The ability of unstimulated splenocytes to enhance 
mitogenesis in thymocytes when the two cell populations 
are cultured together with CON A suggests that some type of 
cellular cooperation (enhancement of LAF production by a 
thymocyte product or direct cellular contact) may be 
.#‘01. t 
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involved. Conditioned medium from unstimulated splenocytes 
did not promote mitogenesis of thymocytes, and in some cases 
it was slightly inhibitory® Gery and Waksman1^ and Mokyr and 
Mitchell0^ postulated that CON A stimulates the thymocyte, 
which causes the splenocyte to produce LAF, which in turn fur¬ 
ther enhances thymocyte DNA synthesis. It would be worthwhile 
to perform a diffusion chamber experiment to determine if solu¬ 
ble factors were responsible for this synergistic phenomenon 
or whether direct cellular contact was required. 
11 
The LAF assay as developed by Gery, Gershon and Waksman 
1 8 
and modified by Blyden and Handschumacher1 was employed 
throughout this study. During the two years in which these 
studies were performed, there was considerable variation in 
the absolute number of counts of radioactive thymidine 
incorporated by the thymocytes. This occurred despite the 
fact that the reagents were not changed (all serum came 
from the same lot) and the mice were obtained from the same 
source. Gross bacterial contamination was quite obvious when 
it occurred and was a problem in only a few experiments. 
Inspection of the actual values obtained for cell-free peri¬ 
toneal exudate and for splenocyte LAF reveals a substantial 
difference in the absolute amount of thymidine incorporation. 
Values for a standard mitogen (CON A) and supernatant frac¬ 
tions prepared from human peripheral blood leukocytes were 
substantially lower than the values seen at other times in 




fraction yielded ~20,000 CPM in the peritoneal exudate stu¬ 
dies and only^2»G0Q in the splenocyte experiments (compared 
to values of ^1,000 for thymocytes cultured without any 
stimulants)® It should be noted that these two sets of 
experiments were performed 12 months apart* Each component 
of the assay was reevaluated, but no reason was found for 
the discrepancy.* It Is possible that a subeXinical viral 
infection could have resulted in a loss of immunocompetence. 
For example, it has been shown that human measles vaccination^! 
and Epstein-Barr viral infection^ (infectious mononucleosis) 
can result in decreased immunocompetence, as measured by 
anergy to the Mantoux tuberculin and Candida Intradermal 
tests and the response of lymphocytes to PHA, pokeweed mitogen 
and allogeneic lymphocytes. 
Since the supernatant fraction of cultured GDI spleno- 
cytes caused mitogenesis of GDI thymocytes, the role of 
strain differences as the sole cause of this phenomenon 
can be excluded. B6D2F1 thymocytes did not respond as well 
as those from the GDI mice, and it is for this reason that 
GDI thymocytes were used in the assay. 
The effect of dialysis on the supernatant fractions 
assayed can be demonstrated by comparing the LAF activity of 
the dialyzed and undialyzed samples from splenocytes incubated 
with medium for various time intervals. The increasing 
difference in LAF activity between dialyzed and undialyzed 




quantities of a dialyzable inhibitor that obscures the eleva¬ 
tion of LAF. Indeed Opitz and his group^0 studied a similar 
suppressor. They found that it merely reduced the incor¬ 
poration of tritiated thymidine* but did not inhibit cell 
proliferation. The factor was heat stable and dialyzable 
and apparently was a cellular degradation product, since it 
was produced when T-lymphocytes and macrophages were culti¬ 
vated together, but not when they were cultured in opposite 
sides of a diffusion chamber. This was consistent with the 
inhibitor being thymidine, which could interfere with 
tritiated thymidine uptake by increasing the ratio of cold 
thymidine to radioactive thymidine in the assay wells. 
Characterization and Purification of LAF 
Preliminary data indicates that the molecular weight of 
murine LAF (55*000 daltons) is much greater than that of the 
LAF obtained from human peripheral blood leukocytes (13*000 
daltons)10* and values previously reported for murine LAF 
(5*000-25*000 daltons^ The value obtained in these 
experiments appears to be similar to the molecular weight of 
the LAF from the murine cell line, P388-DI (80,000 dal tons 
The isoelectric point (pi) of the murine splenic LAF (5*0) 
is similar to that of the murine cell line LAF (pi = 4.8-5*0).35 
1 8 
The pi of the human leukocyte LAF is 6.8-7 • 0. “ 
The molecular weight values were obtained with a rela¬ 
tively small column (25 x 0.5 cm) and each 1 cc fraction 
differed in molecular weight by 10,000 daltons in the range 
, 
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of the peak values® Molecular weight determination with 
larger columns would be useful® The apparent molecular 
weight of the splenic LAF was only approximately twice the 
magnitude of the baseline activity,;, and the significance 
of the secondary peak at 180,000 daltons in one run can 
not be determined® These molecular weights represent 
peaks of activity in the presence of the mitogen, CON A. 
The fractions in the absence of mitogens failed to enhance 
DNA synthesis® Since CON A stimulates immature thymocytes, 
the molecule which enhances the CON A response may be different 
from that which affects another portion of the thymocyte 
population® It is conceivable that the fractions assayed in 
the absence of a mitogen would have produced a peak of acti¬ 
vity corresponding to a different molecular weight® However, 
the fractions of human LAF which maximally enhanced CON A 
induced mitogenesis had the same molecular weight as those 
which enhanced thymocyte mitogenesis in the presence of PHA 
and in the absence of any mitogen® The murine LAF was 
obtained 4 to 6 hours after the animals were injected with 
LPS, and it is possible that LAF with a different molecular 
weight could appear later® 
Implications for Immunotherapy 
This research demonstrates that an intraperitoneal 
endotoxin challenge to a living animal can lead to the rapid 
production of LAF by cells in the peritoneum and spleen. 
The LPS resulted in considerable toxicity, and it would be 
* 
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worthwhile to determine if a derivative of this complex 
material could produce the same LAF response with less toxicity* 
Different routes of endotoxin administration (intravenous or 
subcutaneous) might also be considered. 
The experiments performed measured the amount of LAF in 
the immediate proximity of the cells producing this substance® 
It would be valuable to measure the concentration of this 
substance in the blood stream of mice receiving intraperi- 
toneal LPS. 
One of the distant objectives of these studies is to 
purify LAF and determine if non-specific stimulation of the 
immune system of cancer patients could effect the course of 
their disease. The apparent differences between human and 
murine LAF indicate the need for caution in applying the 
results from one species to another. In preliminary 
experiments (data not included), very crude preparations of 
human and murine LAF were unable to inhibit the growth of 
L1210 leukemia in B6B2F1 mice. Better preparations of LAF 
and different dosage schedules may prove more successful, 
and other tumors may be more responsive than LI210. 
Another possible use of LAF is in the treatment of 
congenital immunodeficiency disease. Although LAF by itself 
will not replace the many components of the immune system, 
it might prove valuable as an adjuvant in treating certain 
diseases. Two diseases in which cell-mediated immunity is 
deficient, mucocutaneous candidiasis and the Wiskott-Aldrich 

4? 
syndrome (eczema, thrombocytopenia and immunodeficiency), 
have responded in some cases to another substance, transfer 
factor* -)f This substance is a dialyzable extract of 
sensitized leukocytes which transfers reactivity from skin 
6? 
test positive donors to skin test negative recipients® It 
is possible that the use of LAF might cause these patients 
to respond immunologically to a wider variety of antigens. 
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